Cardio Diagnostics (CDIO) Competitors

Rallybio (NASDAQ:RLYB) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Do institutionals & insiders have more ownership in RLYB or CDIO?

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 8.7% of Rallybio shares are owned by company insiders. Comparatively, 22.3% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is RLYB or CDIO more profitable?

Rallybio has a net margin of -5,473.33% compared to Cardio Diagnostics' net margin of -30,465.10%. Rallybio's return on equity of -71.66% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-5,473.33%	-71.66%	-65.06%
Cardio Diagnostics	-30,465.10%	-72.78%	-66.17%

Does the media favor RLYB or CDIO?

In the previous week, Rallybio had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Rallybio and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.98 beat Rallybio's score of 0.49 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, RLYB or CDIO?

Rallybio has a beta of -1.12, suggesting that its stock price is 212% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500.

Do analysts recommend RLYB or CDIO?

Rallybio currently has a consensus price target of $10.00, suggesting a potential upside of 1,609.40%. Cardio Diagnostics has a consensus price target of $60.00, suggesting a potential upside of 1,599.24%. Given Rallybio's higher probable upside, research analysts clearly believe Rallybio is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardio Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable earnings and valuation, RLYB or CDIO?

Cardio Diagnostics has lower revenue, but higher earnings than Rallybio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$640K	38.20	-$57.78M	-$0.94	-0.62
Cardio Diagnostics	$40K	155.36	-$8.38M	N/A	N/A

Summary

Rallybio and Cardio Diagnostics tied by winning 7 of the 14 factors compared between the two stocks.